Please provide your email address to receive an email when new articles are posted on . Risk estimation was based on area under the receiver operating characteristic curve, sensitivity and specificity ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...

SAN DIEGO -- The beta-blocker bisoprolol did not improve exacerbations in chronic obstructive pulmonary disease (COPD) patients, a randomized clinical trial found. Exacerbations requiring antibiotics, ...

Tozorakimab, an investigational monoclonal antibody targeting the IL-33 pathway, significantly reduced moderate-to-severe ...

Please provide your email address to receive an email when new articles are posted on . Mortality occurred in more patients with severe vs. mild COPD exacerbation based on Rome severity classification ...

First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III clinical trials Positive ...

AstraZeneca has reported positive high-level results from the phase 3 MIRANDA trial of tozorakimab, showing a statistically significant reduction in moderate-to-severe exacerbations in patients with ...

Changes in people’s voices recoded on a smartphone can signal a serious flare up in symptoms of chronic obstructive pulmonary disease (COPD), according to a pilot study presented at the European ...

Medically reviewed by Brian Bezack, DO Key Takeaways Over-the-counter (OTC) inhalers are not approved for treating COPD.

Altesa BioSciences, a clinical-stage pharmaceutical company dedicated to improving the lives of people with chronic lung diseases including COPD and asthma, today announced the enrollment of the first ...